Outlook is neutral, with stock confined to a range of ±2%
Strategy has +63% ROI potential and 20% overvalued
REGN Regeneron Pharmaceuticals687.19+20.34 (+3.1%)
REGN Regeneron Pharmaceuticals698.62-4.81 (-0.7%)
REGN Regeneron Pharmaceuticals682.98-13.90 (-2.0%)
REGN Regeneron Pharmaceuticals741.43+11.13 (+1.5%)